[Federal Register Volume 83, Number 140 (Friday, July 20, 2018)]
[Notices]
[Page 34599]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2018-15489]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by an agency of the U.S. 
Government and are available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Chris Kornak, 240-627-3705, 
[email protected]. Licensing information and copies of the U.S. 
patent applications listed below may be obtained by communicating with 
the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office (TTIPO), 5601 Fishers Lane, Suite 6D, MSC 
9804, Rockville, MD 20892, tel: 301-496-2644, fax: 240-627-3117. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Inhibition of CD300f Function on Dendritic Cells Promotes Tumor 
Destruction

    Description of Technology: Cancer immunotherapy aims to enhance the 
ability of a patient's own immune response to destroy tumors. The 
magnitude of the immune response is determined by the balance between 
immune activating signals and negative inhibitory signals. Checkpoint 
receptors are negative regulators that normally deliver inhibitory 
signals which limit immune activation. Blockade of immune checkpoints 
represents an effective strategy to enhance the immune response against 
cancer cells.
    NIAID researchers have discovered that blocking CD300f function in 
dendritic cells markedly enhances their ability to phagocytose and 
process apoptotic tumor cells, leading to substantial inhibition of 
tumor growth. In this light, CD300f may be viewed as a dendritic cell 
checkpoint receptor analogous to T cell checkpoint receptors like PD-1 
and CTLA-4. As a result, inhibiting CD300f function on dendritic cells 
could be a promising anti-cancer therapy, especially in the settings 
where blocking of T cell checkpoint receptors has been ineffective.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.
    Potential Commercial Applications:

 Cancer immunotherapy

    Competitive Advantages:

 A novel approach

    Development Stage:

 Pre-Clinical
 Proof-of-concept studies in mouse models

    Inventors: John E. Coligan, Konrad Krzewski, Linjie Tian, Ha-Na 
Lee, all of NIAID, NIH.
    Publications: Tian, L. et al., Enhanced efferocytosis by dendritic 
cells underlies memory T-cell expansion and susceptibility to 
autoimmune disease in CD300f-deficient mice. Cell Death and Differ 
(2016) 23, 1086-1096.
    Intellectual Property: HHS Reference No. E-257-2016/0--U.S. Patent 
Application No. 62/408,596 filed on 10/14/2016;--PCT/US2017/056192 
filed on 10/11/2017.
    Licensing Contact: Chris Kornak, 240-627-3705, 
[email protected].
    Collaborative Research Opportunity: The Technology Transfer and 
Intellectual Property Office (TTIPO) is not seeking parties interested 
in collaborative research to further develop the technology.

    Dated: July 9, 2018.
Suzanne M. Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2018-15489 Filed 7-19-18; 8:45 am]
 BILLING CODE 4140-01-P